Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) EBT Margin (2019 - 2025)

Eton Pharmaceuticals' EBT Margin history spans 7 years, with the latest figure at 5.11% for Q3 2025.

  • For Q3 2025, EBT Margin fell 997.0% year-over-year to 5.11%; the TTM value through Sep 2025 reached 9.22%, up 6.0%, while the annual FY2024 figure was 9.76%, 758.0% down from the prior year.
  • EBT Margin for Q3 2025 was 5.11% at Eton Pharmaceuticals, up from 13.31% in the prior quarter.
  • Across five years, EBT Margin topped out at 43.0% in Q1 2021 and bottomed at 786.32% in Q3 2021.
  • The 5-year median for EBT Margin is 10.18% (2024), against an average of 70.53%.
  • The largest YoY upside for EBT Margin was 2358427bps in 2021 against a maximum downside of -25621628bps in 2021.
  • A 5-year view of EBT Margin shows it stood at 17.05% in 2021, then plummeted by -37bps to 10.73% in 2022, then crashed by -163bps to 6.74% in 2023, then soared by 35bps to 4.39% in 2024, then dropped by -17bps to 5.11% in 2025.
  • Per Business Quant, the three most recent readings for ETON's EBT Margin are 5.11% (Q3 2025), 13.31% (Q2 2025), and 99.87% (Q1 2025).